Treat infants for RDS with CUROSURF

In comparative trials, the data support a consistent survival advantage for infants receiving CUROSURF versus those receiving Survanta^®. Although the data show a trend, it’s important to note that these trials were not powered to evaluate mortality as a primary outcome.^1-3

Table of survival findings across studies with CUROSURF

Through each study, there was a consistent survival advantage for patients receiving CUROSURF.^1-3

*Mortality was evaluated in infants with moderate to severe RDS.
†Mortality was evaluated as a secondary end point.

CUROSURF has no negative long-term impact on infant development

In a 2-year follow-up study, patients treated with CUROSURF showed no identifiable long-term impact on physical growth, prevalence of disability, or immunological sensitization to CUROSURF.⁴

More efficacy data: See how CUROSURF demonstrates a rapid onset of action, sustained results with fewer doses, and facilitates success with less invasive ventilation for fast RDS success.

CUROSURF facilitates efficient administration.

Interested in evaluating CUROSURF? Find out how you can smoothly integrate CUROSURF into your NICU by participating in the CUROSURF Experience Program.

Clinical studies have not established that fewer doses, lower volume, or longer dosing intervals result in superior safety or efficacy based on clinically relevant end points.

Indication

CUROSURF^® (poractant alfa) Intratracheal Suspension is indicated for the treatment (rescue) of respiratory distress syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Important Safety Information

CUROSURF is intended for intratracheal use only. THE ADMINISTRATION OF EXOGENOUS SURFACTANTS, INCLUDING CUROSURF, CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified in response to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

TRANSIENT ADVERSE EFFECTS SEEN WITH THE ADMINISTRATION OF CUROSURF INCLUDE BRADYCARDIA, HYPOTENSION, ENDOTRACHEAL TUBE BLOCKAGE, AND OXYGEN DESATURATION. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Click here for full prescribing information

This site is intended for United States residents only.

Survanta^® is a registered trademark of Abbott Laboratories, Inc.

References: 1. Malloy CA, Nicoski P, Muraskas JK. Acta Paediatr. 2005;94:779-784. 2. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; and The North American Study Group. Am J Perinatol. 2004;21:109-119. 3. Speer CP, Gefeller O, Groneck P, et al. Arch Dis Child. 1995;72:F8-F13. 4. Robertson B, Curstedt T, Tubman R, et al. Eur J Pediatr. 1992;151:372-376.